BioRevolution is dedicated to building, restoring, and preserving muscle mass and strength for longevity. Our lead program, BREV-100, harness the body’s central mechanism of building functional muscle, mimicking the adaptive signals of intense resistance training across multiple muscle wasting diseases, including Glycogen Storage Disorders, Muscular Dystrophies, GLP-1–associated muscle wasting, and Sarcopenia.
Muscle Drives Movement, Metabolism, and Vital Internal Functions. BioRevolution Develops Metabolic and Regenerative Therapies That Rebuild Strength Across Rare and Chronic Muscle Diseases.
Estimated Number of People Globally Experiencing Muscle Wasting Related Diseases
Skeletal Muscle Accounts for ~40% of Total Body Mass and Is a Key Regulator of Metabolism, Glucose Homeostasis, and Survival
Muscle loss is central to glycogen storage diseases such as Pompe and rare genetic neuromuscular diseases such as DMD, driving progressive and disabling weakness
Muscle loss is a debilitating feature of heart failure, chronic kidney disease (CKD), and type 2 diabetes, driven by inflammation, hormonal changes, and metabolic dysfunction
Corticosteroids and chemotherapy cause direct muscle loss, while GLP-1 therapies can indirectly lead to muscle loss via reduced appetite and caloric intake
Sarcopenia affects millions, with adults over 35 losing 1-2% of their muscle each year and it accelerates after 60 driving frailty, loss of mobility, and higher mortality
Skeletal Muscle System
Essential for longevity, driving metabolic health, strength, and survival.
Respiratory & Diaphragm Muscles
Support respiration, oxygen exchange, and stamina.
Lower Limb & Mobility Muscles
Enable walking, balance, and mobility.
Upper Limb Muscles
Power arms, grip, and functional tasks.
Core & Trunk Muscles
Enable posture, rotation, and control.
Our initial focus is on Pompe disease where glycogen accumulation impairs muscle function leading to severe disability and premature death. Ultimately, we aim to expand to broader indications characterized by metabolic defects (e.g., autophagy block, glycolysis defects in DMD), impaired proteostasis and mitochondrial dysfunction (sarcopenia), and energy restriction with reduced anabolic signaling (GLP-1–associated muscle loss).
BREV-100 is a first-in-class oral small molecule designed to address Pompe disease by:
| Lead Program | Disease | Early Pre-Clinical | In-Vivo Efficacy | IND-Enabling Studies | Phase 1 | Global Rights | Next Milestone |
|---|---|---|---|---|---|---|---|
| Genetic Diseases | Other Glycogen Storage Diseases | Pompe Disease | IND-Enabling Studies | ||||
BREV-100First-in-Class, Oral, Small Molecule |
Muscular Dystrophies | In-Vivo Efficacy Studies to validate Development Candidate | |||||
| GLP-1 Induced Muscle Wasting in Obesity | In-Vivo Efficacy Studies to validate Development Candidate | ||||||
| Sarcopenia | In-Vivo Efficacy Studies to validate Development Candidate |
BioRevolution is founded and led by a seasoned team united by a singular mission to transform muscle biology and extend healthy human life for millions living with rare and chronic diseases.
Co-Founder & Chief Executive Officer
Thomas Butler is a seasoned biotech executive with a proven track record of founding and scaling clinical-stage biopharmaceutical companies.
Prior to founding BioRevolution as part of Nutide Venture portfolio, Thomas was the co-founder, Chief Executive Officer, and Chairman of the Board of Biomea Fusion, Inc., where he built the company from the ground up as employee number one. He led the company for 8 years from Lead Identification to Candidate Selection to IND-enabling studies, three funding (up) rounds including a $350M raise, and five clinical trials across 300+ patients. He built Biomea Fusion into an innovative covalent-based Drug Discovery and Development company with a first-class team of biotech professionals to execute on at least three key programs. That included icovamenib (BMF-219), a first-in-class menin inhibitor for diabetes and oncology, BMF-500, a covalent FLT3 inhibitor, as well as a potential best in class small molecule, oral, GLP-1 agonist, BMF-650.
Prior to founding Biomea Fusion in 2017, Thomas co-founded Point Sur Investors, a long-only biotech investment fund focused solely on innovative therapies that significantly improve the standard of care where he served as Managing Partner. Before forming Point Sur Investors, Thomas managed Investor Relations at Pharmacyclics Inc., where he helped grow the company from a market cap of $6.74B to over $21B, which included the execution of one of the largest biotech acquisitions to date. Prior to Pharmacyclics, Inc., Thomas spent 6 years as a medicinal chemist at Gilead Sciences Inc. engaging in novel drug design and drug development of HCV polymerase and protease inhibitors. Thomas is the co-inventor of VEKLURY (Remdesivir), a polymerase inhibitor for the treatment of COVID-19 infection. Remdesivir generated revenue in 2021 of $5.6B.
Thomas holds an MBA from the University of California Los Angeles (UCLA) and a master’s degree in Organic Chemistry from the University of California Santa Barbara (UCSB). As a research scientist, Thomas has been awarded numerous patents in the US and internationally, as well as published in top academic journals such as the American Chemical Society Journal of Medicinal Chemistry and Angewandte Chemie.
Co-Founder & Chief Scientific Officer
Oliver Saunders an accomplished antiviral chemist and drug development leader with over 25 years of experience in research and therapeutic innovation, including 19 years specializing in nucleoside and nucleotide chemistry. Prior to founding BioRevolution, Oliver worked at Gilead Sciences where he contributed to antiviral programs spanning HCV, HIV, RSV, Ebola, and SARS-CoV-1, and, together with Thomas, is a co-inventor of VEKLURY® (Remdesivir), a polymerase inhibitor developed for the treatment of COVID-19. Previously, Oliver led Novartis’ antiviral nucleoside team, advancing programs targeting HCV, HRV, and Dengue. At BioRevolution, Oliver leverages his deep translational expertise to guide BREV-100 discovery and mechanistic rational to position BREV-100 for maximal impact in muscle health and longevity.
Chief Business Officer
Thanaa Makdsi is an accomplished biotech professional with experience spanning finance, investing, sell-side equity research, corporate development, and investor relations across the biotech sector.
Prior to launching BioRevolution as part of Nutide Venture portfolio, Thanaa served as Associate Director of Investor Relations at ACELYRIN, where she led efforts to identify and engage new investors, analyze market dynamics in inflammatory diseases, and support the overall investor and analyst communications strategy. She previously held corporate development and investor relations roles at Senti Biosciences, where she supported a $296 million fundraising and public listing, along with ongoing investor relations and business development initiatives.
Earlier in her career, Thanaa was a sell-side equity research associate at Wedbush Securities, covering public and private biotech companies across neurology and nephrology, and evaluating development strategies and competitive positioning. She also served as a buy-side equity research analyst at Point Sur Investors, conducting fundamental analysis of small- and mid-cap biotech companies across multiple therapeutic areas. There, she helped shape the development strategy for a public biotech company leading to a $26 million raise and supported the early operations of portfolio company Biomea Fusion.
Thanaa holds a BS in Finance with honors and a minor in Applied Computing from San Jose State University.
Head of INTELLECTUAL PROPERTY
Ravi Upasani, Ph.D. brings over three decades of experience spanning drug discovery and intellectual property management across the biotechnology and pharmaceutical industries. Trained as a small molecule chemist, Ravi combines a deep understanding of medicinal chemistry and structure–activity relationships with extensive expertise in global patent strategy and portfolio development.
Prior to BioRevolution, Ravi served as Executive Vice President of Intellectual Property at Biomea Fusion, where he built and led the company’s IP function, developing and executing comprehensive strategies to protect its covalent chemistry platform and clinical-stage oncology and metabolic programs. His leadership encompassed the creation and prosecution of foundational patent families, competitive landscape assessments, and IP diligence.
Prior to Biomea Fusion, Ravi held senior intellectual property positions at Protagonist Therapeutics, Pharmacyclics, Evotec, and Renovis, where he directed patent strategies across diverse therapeutic areas including oncology, inflammation, CNS disorders, and metabolic diseases. Over the course of his career, he has contributed to multiple IND-enabling programs and clinical candidates, guiding the integration of scientific innovation with robust IP protection to support long-term value creation.
Ravi is a registered U.S. Patent Agent with the U.S. Patent and Trademark Office (USPTO). He has authored more than 35 scientific publications and is listed as an inventor on over 15 U.S. patents, reflecting both his technical depth in medicinal chemistry and his strategic acumen in intellectual property management.